SITRAVATINIB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ACHIRAL
Molecular Formula	C33H29F2N5O4S
Molecular Weight	629.676
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of SITRAVATINIB

Structure Search

SMILES

COCCNCC1=CN=C(C=C1)C2=CC3=NC=CC(OC4=CC=C(NC(=O)C5(CC5)C(=O)NC6=CC=C(F)C=C6)C=C4F)=C3S2

InChI

InChIKey=WLAVZAAODLTUSW-UHFFFAOYSA-N

InChI=1S/C33H29F2N5O4S/c1-43-15-14-36-18-20-2-8-25(38-19-20)29-17-26-30(45-29)28(10-13-37-26)44-27-9-7-23(16-24(27)35)40-32(42)33(11-12-33)31(41)39-22-5-3-21(34)4-6-22/h2-10,13,16-17,19,36H,11-12,14-15,18H2,1H3,(H,39,41)(H,40,42)

HIDE SMILES / InChI

Molecular Formula	C33H29F2N5O4S
Molecular Weight	629.676
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 10:07:46 UTC 2023` Edited by `admin` on `Sat Dec 16 10:07:46 UTC 2023`
Record UNII	CWG62Q1VTB
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SITRAVATINIB

Official Name

English

SITRAVATINIB [USAN]

Common Name

English

MGCD-516

Code

English

Sitravatinib [WHO-DD]

Common Name

English

MG-516

Code

English

MG-91516

Code

English

sitravatinib [INN]

Common Name

English

1,1-CYCLOPROPANEDICARBOXAMIDE, N-(3-FLUORO-4-((2-(5-(((2-METHOXYETHYL)AMINO)METHYL)-2-PYRIDINYL)THIENO(3,2-B)PYRIDIN-7-YL)OXY)PHENYL)-N'-(4-FLUOROPHENYL)-

Systematic Name

English

MGCD516

Code

English

N-(3-FLUORO-4-((2-(5-(((2-METHOXYETHYL)AMINO)METHYL)PYRIDIN-2-YL)THIENO(3,2-B)PYRIDIN-7-YL)OXY)PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1967

Created by admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023

NCI_THESAURUS

C1742

Created by admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023

NCI_THESAURUS

C129825

Created by admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023

Code System Code Type Description

FDA UNII

CWG62Q1VTB

Created by admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023

PRIMARY

CAS

1123837-84-2

Created by admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023

PRIMARY

EPA CompTox

DTXSID801100124

Created by admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023

PRIMARY

MANUFACTURER PRODUCT INFORMATION

SITRAVATINIB

Created by admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023

PRIMARY

MedKoo CAT NO: 206510; CAS NO: 1123837-84-2; Description: Sitravatinib, also known as MGCD516 or MG516, is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth. MGCD516 treatment resulted in significant blockade of phosphorylation of potential driver RTKs and induced potent anti-proliferative effects in vitro. MGCD516 treatment of tumor xenografts in vivo resulted in significant suppression of tumor growth. (last updated: 12/28/2015).

NCI_THESAURUS

C117734

Created by admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023

PRIMARY

INN

10216

Created by admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023

PRIMARY

WIKIPEDIA

Sitravatinib

Created by admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023

PRIMARY

DRUG BANK

DB15036

Created by admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023

PRIMARY

PUBCHEM

25212148

Created by admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023

PRIMARY

USAN

DE-140

Created by admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023

PRIMARY

SMS_ID

100000172780

Created by admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023

PRIMARY

Related Record Type Details


					ZR2110H6XE

SITRAVATINIB MALATE

SALT/SOLVATE -> PARENT

Amount:


					ZQ5EFJ7XNX

TYROSINE-PROTEIN KINASE RECEPTOR TYRO3

TARGET -> INHIBITOR

Amount:


					CE55KZ8SI1

TYROSINE-PROTEIN KINASE MER

TARGET -> INHIBITOR

Amount:


					OVI08ABI5H

MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT

TARGET -> INHIBITOR

Amount:


					8EJE45ZR0I

TYROSINE-PROTEIN KINASE RECEPTOR UFO

TARGET -> INHIBITOR

Amount:


					798536Z7S0

VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2

TARGET -> INHIBITOR

Amount:


					22ES734693

MULTIDRUG RESISTANCE PROTEIN 1

TRANSPORTER -> INHIBITOR

Comments:

Inhibits the ABCB1 efflux pump by inhibiting the hydrolysis of ATP

Amount:

Related Record Type Details


					CWG62Q1VTB

ACTIVE MOIETY

Comments:

Originator: MethylGene; Developer: Mirati Therapeutics; Class: Antineoplastic, Small molecule Mechanism of Action: Axl receptor tyrosine kinase inhibitor, Eph family receptor antagonist, Platelet-derived growth factor receptor antagonist, Proto oncogene protein c met inhibitor, Proto oncogene protein c ret inhibitor, Proto oncogene protein c-kit inhibitor, Proto-oncogene protein c-mer inhibitor, Receptor protein-tyrosine kinase antagonist, RON protein inhibitor, TIE 2 receptor antagonist, Tropomyosin-related kinase antagonist, Vascular endothelial growth factor receptor 3 antagonist, Vascular endothelial growth factor receptor-1 antagonist, Vascular endothelial growth factor receptor-2 antagonist; New Molecular Entity: Yes; Highest Development Phase: Phase I for Solid tumours; Most Recent Events: 06 Jun 2016 Adverse events, pharmacokinetics, pharmacodynamics and efficacy data from a phase I trial in Solid tumour released by Mirati Therapeutics (3187888, 9197140), 30 Sep 2015 Interim adverse events and PK data from a phase I/Ib trial in solid tumours presented at the European Cancer Congress (ECC-2015), 04 Sep 2014 Mirati Therapeutics initiates dosing in a phase I trial of Sitravatinib in Solid tumours (advanced disease)

Amount: